CytomX Therapeutics (CTMX) Goodwill & Intangibles (2014 - 2026)

CytomX Therapeutics has reported Goodwill & Intangibles for 13 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 9.76% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 9.76% YoY), and the FY2025 full-year result was $1.4 million, down 9.46% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $1.3 million, down from $1.4 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $1.9 million in Q1 2022, with the low at $1.3 million in Q1 2026.
• Historically, Goodwill & Intangibles has averaged $1.6 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles dropped 7.02% — and 2026, when it declined 9.76%.
• CytomX Therapeutics' Goodwill & Intangibles stood at $1.8 million in 2022, then retreated by 8.0% to $1.7 million in 2023, then fell by 8.7% to $1.5 million in 2024, then decreased by 9.46% to $1.4 million in 2025, then fell by 2.67% to $1.3 million in 2026.
• The last three Goodwill & Intangibles figures came in at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.